Exploring Stereotaxis's Role in Surgical Robotics
ST. LOUIS — Stereotaxis (NYSE: STXS), recognized as a leader in surgical robotics for minimally invasive endovascular interventions, is preparing to showcase its advancements at the notable TD Cowen 45th Annual Healthcare Conference. David Fischel, the current Chairman and CEO of Stereotaxis, will represent the company and share insights into its innovations and strategic initiatives.
Conference Details
During the conference, scheduled for March 3, David will deliver a comprehensive overview of Stereotaxis, highlighting its vision and accomplishments at 3:10 PM ET. This platform presents a unique opportunity for the company to not only discuss its progress but also to engage in one-on-one discussions that day.
CEO's Perspective
Fischel expresses enthusiasm about the conference stating, "We appreciate the opportunity to participate in the TD Cowen Healthcare Conference and look forward to sharing our progress and strategy." This engagement underscores Stereotaxis's commitment to innovation and partnership within the healthcare community.
About Stereotaxis's Innovations
Stereotaxis is on the forefront of surgical robotics, dedicated to enhancing the field of minimally invasive endovascular procedures. The company's mission focuses on discovering, developing, and delivering state-of-the-art robotic systems, instruments, and information solutions tailored for interventional laboratories. Each innovation is crafted to assist physicians in delivering exceptional patient care characterized by robotic precision and safety. Moreover, these advancements are designed to broaden access to minimally invasive therapies, while simultaneously boosting productivity and connectivity in the operating room.
The Impact of Stereotaxis Technology
Impressively, Stereotaxis technology has successfully treated over 150,000 patients globally, including regions such as the United States, Europe, and Asia. The scalable nature of their robotic solutions showcases the company's mission to enhance patient outcomes through advanced medical technology.
Contacting Stereotaxis
If you're looking for further insights into Stereotaxis, you may reach out to their leadership team. David L. Fischel serves as the Chairman and Chief Executive Officer, with Kimberly Peery as the Chief Financial Officer. For inquiries, contact them at 314-678-6100 or via email at Investors@Stereotaxis.com.
Frequently Asked Questions
What is the TD Cowen Healthcare Conference?
The TD Cowen Healthcare Conference is an annual event where healthcare companies present their strategies and innovations to investors and industry peers.
Who will represent Stereotaxis at the conference?
David Fischel, the Chairman and CEO of Stereotaxis, will be representing the company and presenting its overview.
What is Stereotaxis known for?
Stereotaxis is known for its pioneering work in surgical robotics, specifically aimed at improving minimally invasive endovascular interventions.
How many patients have been treated with Stereotaxis technology?
To date, Stereotaxis technology has been utilized to treat more than 150,000 patients worldwide.
How can I contact Stereotaxis for more information?
You can contact Stereotaxis at 314-678-6100 or via email at Investors@Stereotaxis.com for more information.
